Revenue after tax rose to $7 billion final 12 months, up from $6 billion in 2023, the corporate mentioned, noting a pointy enhance in gross sales of most cancers medicines. Learn Extra
AstraZeneca sees earnings surge regardless of Chinese language import tax allegations
Leave a comment
